To the best of our knowledge, the present study is the first reported case with a clinical response to EGFR-TKIs in a patient with lung adenocarcinoma harbouring the EML4-ALK fusion gene and in the absence of EGFR mutations. This evidence concerns the gene ALK and lung adenocarcinoma.